Literature DB >> 11159221

Monitoring end-tidal carbon dioxide during weaning from cardiopulmonary bypass in patients without significant lung disease.

A Maslow1, G Stearns, A Bert, W Feng, D Price, C Schwartz, S MacKinnon, F Rotenberg, R Hopkins, G Cooper, A Singh, S Loring.   

Abstract

End-tidal carbon dioxide tension (PETCO(2)) changes with fluctuations in cardiac output (CO). We compared PETCO(2) to pulmonary artery blood flow (PAQt) during weaning from cardiopulmonary bypass (CPB) in normothermic patients without significant pulmonary disease. Fifteen consecutive adult cardiac surgical patients were prospectively studied during and shortly after weaning from CPB. Before separation from CPB, PETCO(2) and PAQt were measured, the latter by transesophageal Doppler echocardiography. At the time of measurements patients were normothermic, and ventilated at 6 breaths/min with tidal volumes of 10 mL/kg. After separation from CPB, thermodilution cardiac output (TDCO) was measured in addition to PAQt and PETCO(2). Regression and bias analyses were used to compare PETCO(2), PAQt, and TDCO. Seventy measurements were recorded; 31 before separation from CPB and 39 after separation from CPB. A good correlation was seen between PAQt and PETCO(2) (r = 0.88) and between TDCO and PAQt (r = 0.93; mean bias 0.03 L/min; SD 0.52 L/min). The regression analysis of PAQt on PETCO(2) showed greater variability at PETCO(2) levels > 34 mm Hg (n = 22; r = 0.14). Increases in PETCO(2) plateaued at this level, although PAQt continued to increase. When PETCO(2) was more than 30 mm Hg, all PAQt and TDCO values were >4.0 L/min (>2.0 L/min/m(2)). When PETCO(2) exceeded 34 mm Hg, all values of PAQt, and 28/29 values of TDCO were more than 5 L/min (>2.5 L/min/m(2)). One patient had TDCO of 4.69 L/min (2.39 L/min/m(2)). In normothermic patients without significant pulmonary disease, PETCO(2) is a useful index of PAQt during separation from CPB. Under the clinical settings in this study, a PETCO(2) greater than 30 mm Hg was invariably associated with a CO more than 4.0 L/min or a cardiac index >2.0 L/min/m(2).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159221     DOI: 10.1097/00000539-200102000-00004

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Intrathecal fentanyl blockade of afferent neural feedback from skeletal muscle during exercise in heart failure patients: Influence on circulatory power and pulmonary vascular capacitance.

Authors:  Erik H Van Iterson; Eric M Snyder; Michael J Joyner; Bruce D Johnson; Thomas P Olson
Journal:  Int J Cardiol       Date:  2015-08-14       Impact factor: 4.164

2.  A system of classification for the clinical applications of capnography.

Authors:  Naveen Eipe; Jordan Tarshis
Journal:  J Clin Monit Comput       Date:  2007-10-09       Impact factor: 2.502

3.  Intraoperative end-tidal carbon dioxide concentrations: what is the target?

Authors:  Megan Way; Gary E Hill
Journal:  Anesthesiol Res Pract       Date:  2011-10-25

4.  In emergently ventilated trauma patients, low end-tidal CO2 and low cardiac output are associated and correlate with hemodynamic instability, hemorrhage, abnormal pupils, and death.

Authors:  C Michael Dunham; Thomas J Chirichella; Brian S Gruber; Jonathan P Ferrari; Joseph A Martin; Brenda A Luchs; Barbara M Hileman; Renee Merrell
Journal:  BMC Anesthesiol       Date:  2013-09-11       Impact factor: 2.217

5.  Not Bad: Passive Leg Raising in Cardiopulmonary Resuscitation-A New Modeling Study.

Authors:  Yanru Zhang; María Jiménez-Herrera; Christer Axelsson; Yunzhang Cheng
Journal:  Front Physiol       Date:  2017-01-09       Impact factor: 4.566

6.  Pulse pressure and end-tidal carbon dioxide for monitoring low native cardiac output during veno-arterial ECLS: a prospective observational study.

Authors:  Marc Mourad; Jacob Eliet; Norddine Zeroual; Marine Saour; Pierre Sentenac; Federico Manna; Nicolas Molinari; Thomas Gandet; Pascal H Colson; Philippe Gaudard
Journal:  Crit Care       Date:  2020-09-22       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.